中华医学会日前在北京正式发布了《内科住院患者静脉血栓栓塞症预防的中国专家建议》。
"Chinese medical Association recently published in Beijing," medical patients to prevent venous thromboembolism in the Chinese experts recommend.
结论(1)静脉血栓栓塞症高危患者需行手术和发生创伤时，应采取措施预防静脉血栓栓塞症。
Conclusion (1) Prophylaxis way should be taken to prevent VTE while VTE high risk patients were operated or had trauma.
目的评估神经外科患者在围手术期皮下注射低分子肝素预防深静脉血栓栓塞症的安全性及有效性。
Objective To evaluate the safety and availability of prophylactic treatment for venous thromboembolism by hypodermic injection of low-molecule-weight heparin (LMWH) during peri-operation period.
致命性静脉血栓栓塞症以及伴出血的肺栓塞是较容易的，因为他们的发生率均在1%左右，尽管华法林可能会发生致命的出血。
Balancing the rates of risk of fatal VTE or PE with bleeding is about easier since they are both about 1%, although fatal bleeding with warfarin can occur.
静脉血栓性疾病(下肢深静脉血栓及肺栓塞)是骨科术后致命的、严重的并发症。
Background venous thromboembolic disease, including deep venous thrombosis and pulmonary embolism, is a serious and potentially life-threatening complication following orthopaedic surgical procedures.
目的评价介入微创伤治疗深静脉血栓及其并发症巨块型肺动脉血栓栓塞的安全性和效果。
Objective To assess the efficacy and safety of the interventional techniques for treatment of deep venous thrombosis (DVT) and acute massive pulmonary thromboembolism (PTE).
研究中未发现出现并发症，如肺栓塞或深静脉血栓等。
No complications, such as pulmonary emboli or deep vein thrombosis, were noted in the study.
全部病例均获得骨性愈合，平均愈合时间3.3个月(3 ~ 4.5个月)。未发生深部感染、下肢深静脉血栓、肺栓塞、骨不连等并发症。
All the cases obtained bone union in average 3.3 months (from 3 to 4.5 months). There were no complications such as deep infection, deep vein thrombosis, pulmonary embolism and bone nonunion.
术中及术后未见深静脉血栓及肺动脉栓塞等严重并发症。
But, no serious complications, such as deep venous thrombosis or pulmonary embolism, were observed.
杂合子i型(定量)和大多数II型(定性)抗凝血酶缺乏症使静脉血栓栓塞(VTE)的风险显着增加，而纯合型突变会导致死亡。
Heterozygous type I (quantitative) and most type II (qualitative) antithrombin deficiencies highly increase the risk of venous thromboembolism (VTE), while homozygous mutations are lethal.
杂合子i型(定量)和大多数II型(定性)抗凝血酶缺乏症使静脉血栓栓塞(VTE)的风险显着增加，而纯合型突变会导致死亡。
Heterozygous type I (quantitative) and most type II (qualitative) antithrombin deficiencies highly increase the risk of venous thromboembolism (VTE), while homozygous mutations are lethal.
应用推荐